Toll Healthcare expands partnership with CSL Seqirus

Toll Group has announced the construction of a new, 10,000 sq m healthcare facility at Tullamarine, near Melbourne. Toll is a leading supply chain partner to CSL Seqirus, and the facility is being custom built to support CSL Seqirus’ operations.

The warehouse and distribution centre will be situated next to the future CSL Seqirus manufacturing site, bolstering Toll’s tailored support for CSL Seqirus by handling both finished goods distribution and supplying raw materials and packaging to the CSL Seqirus manufacturing facility.

Toll’s warehouse and distribution centre is due to commence operations in August 2024.

The new warehouse marks Toll’s commitment to providing comprehensive logistics solutions for the healthcare sector. With operations commencing in Tullamarine, Toll aims to enhance efficiency and timeliness through just-in-time services. The collaboration between Toll and CSL Seqirus underscores a shared dedication to innovation and excellence in healthcare logistics.

“We are proud to strengthen our partnership with CSL Seqirus and expand our footprint in the healthcare logistics sector,” said Perry Singh, President, Government & Defence at Toll.

In addition to the Tullamarine facility, in April 2023 Toll opened new warehouse in Richlands, Queensland, further demonstrating its dedication to enhancing healthcare logistics infrastructure across Australia.

“The facilities are part of Toll’s broader multi-million-dollar investment creating advanced warehouse management solutions to meet the changing dynamics in the healthcare sector, and providing customers with the logistical support they need,” Singh said.

Toll’s facility will be situated adjacent to the soon-to-be-completed CSL Seqirus plant, a new biotech manufacturing facility in Australia which will supply influenza vaccines to Australia and the rest of the world. The facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

Source: Toll Group